Aktobe

Researchers are investigating pancreatic function in adults with type 2 diabetes to better understand both hormone production and digestive processes. This observational study aims to identify whether pancreatic problems can help detect pancreatogenic diabetes and how blood markers and pancreas structure relate to pancreatic function. The study is conducted as a cross-sectional, single-region, multisite investigation in outpatient clinics in the Aktobe region, Kazakhstan, focusing on adults with type 2 diabetes diagnosed within the past five years. Participants will attend a single visit during which blood tests will measure glucose, insulin, and other relevant markers. They will provide a stool sample to evaluate digestive function and undergo ultrasound imaging of the pancreas. Additionally, participants will answer questions about digestive symptoms to assess pancreatic exocrine function. The study groups include adults with type 2 diabetes who do not have exocrine pancreatic insufficiency based on fecal elastase-1 levels or questionnaire results. During the visit, researchers will collect and analyze various biochemical and imaging data, including fecal elastase-1, pancreatic ultrasound parameters, and blood markers such as C-peptide and glycated hemoglobin. Outcome measures will focus on the prevalence of pancreatogenic diabetes at the baseline visit. The study does not involve treatment but aims to improve diagnostic understanding through these comprehensive assessments. Total participation involves this single outpatient visit with no further follow-up required.

This research aims to collect real-world data on the characteristics, management, healthcare use, and outcomes of patients living with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It is an international observational registry that includes patients from many countries to better understand how these conditions are treated in everyday clinical practice. Participants in this registry are observed without receiving experimental treatments. Data are collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry includes groups of patients with type 2 diabetes, hypertension, chronic kidney disease, or heart failure, either as their primary condition or as a coexisting condition. Patients provide information about their health status, treatments, and outcomes over time. Researchers collect data on demographics, disease characteristics, laboratory tests, treatments, healthcare visits, hospitalizations, and lifestyle factors. The study measures many outcomes such as blood sugar levels, kidney function, heart function, medication use, and health events over an average of three years. Participation is voluntary and ongoing, with data collection continuing until the study end date in 2030.

Researchers are conducting the INTERSTELLAR study to gather important real-world evidence about adding anifrolumab to the usual treatment for systemic lupus erythematosus SLE. This observational study is taking place across multiple countries, including regions like GCC, Mexico, Central America, Colombia, Argentina, Taiwan, and Egypt. It aims to provide data useful for doctors, payers, and patients by using consistent criteria and measures for SLE and skin symptoms related to lupus. Participants will be observed for one year before starting anifrolumab and followed for one year after beginning treatment. The study starts after anifrolumabs commercial launch in each country and includes patients from the time of their first anifrolumab prescription and infusion. Data collection continues even if participants stop taking anifrolumab, unless they withdraw their consent. During the study, clinical assessments and patient-reported outcomes will be collected at baseline and at months 1, 3, 6, and 12. These include disease activity scores PGA, SLEDAI-2K, skin involvement measures CLASI, fatigue assessments FACIT-Fatigue, and quality of life questionnaires LupusQoL, EQ-5D-5L. The study monitors participants until death, loss to follow-up, withdrawal, or study end, aiming to reflect real-world use and outcomes of anifrolumab in routine care.